Blopress led sluggish Japanese market in 2008
12 March 2009
Ian Haydock
Takeda's Blopress (candesartan) was again the top-selling prescription drug in Japan last year, although growth for both it and the wider market was constrained by the regular reimbursement price cut in April. This averaged 5.2% and meant that the total market expanded by just 3% to ¥8,254.3...
Please Login to read the full article.